• Species Reactivity

  Human

• Specificity

  Detects human TFPI in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse TFPI or recombinant human TFPI-2 is observed.

• Source

  Monoclonal Mouse IgG    _2A Clone # 374720

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human TFPI    
  Asp29-Lys282    
  Accession # P10646

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 µg/mL

  Recombinant Human TFPI (Catalog # ) under non-reducing conditions only

• 
  

• Immunoprecipitation

  25 µg/mL

  Conditioned cell culture medium spiked with Recombinant Human TFPI (Catalog # ),

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TFPI

Human TFPI, also known as lipoprotein-associated coagulation inhibitor (LACI) and extrinsic pathway inhibitor (EPI), is a physiological inhibitor of extrinsic pathway of coagulation and has biological functions of anticoagulation and anti-inflammation (1). It is a secreted protein with a N-terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C-terminal basic region (2). The first K domain (residues 54 to 104) inhibits coagulation factor VIIa complexed to tissue factor (TF). The second K domain (residues 125 to 175) inhibits factor Xa. The third K domain (residues 217 to 267) binds to heparin (3). The C-terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces (2).

• References:

1. Bai, H. et al. (2005) Thromb Haemost. 93:1055.

2. Bajaj, M.S. et al. (2001) Thromb Haemost. 86:959.

3. Mine, S. et al. (2002) Biochemistry 41:78.

• Long Name:

  Tissue Factor Pathway Inhibitor

• Entrez Gene IDs:

  7035 (Human); 21788 (Mouse)

• Alternate Names:

  convertin; EPI; EPITFPI1LACITFI; Extrinsic pathway inhibitor; LACI; Lipoprotein-associated coagulation inhibitor; TFPI; tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor); tissue factor pathway inhibitor